Q3 2026 earnings snapshot

McKesson (MCK) has reported Q3 2026 revenue of about US$106.2b and basic EPS of US$9.63, with trailing twelve month EPS at US$34.93 on revenue of roughly US$398.0b. This gives investors a clear read on the latest step in its earnings run rate. The company has seen quarterly revenue move from about US$95.3b in Q3 2025 to US$106.2b in Q3 2026, while basic EPS shifted from US$6.98 to US$9.63 over the same period. This sets the stage for investors to weigh higher earnings against how margins are evolving through the year.

See our full analysis for McKesson.

With the headline numbers on the table, the next step is to see how these results line up with the prevailing growth and risk narratives that investors have been using to frame McKesson over the past year.

Earnings growth outpaces revenue trends

• Over the last 12 months, net income excluding extra items is reported at US$4.3b on revenue of US$398.0b, with trailing EPS at US$34.93 compared with US$25.08 a year earlier.
• Consensus narrative points to earnings growth being driven by expansion in specialty pharmaceuticals and value added services. The current figures show that reported earnings growth of 53.6% over the past year has outpaced forecast revenue growth of about 7.6% per year, which may prompt investors to ask how much of this earnings strength is tied to mix and efficiency rather than volume alone.
  • The trailing net profit margin of 1.1% compared with 0.8% last year aligns with the view that operational efficiency and higher value services are contributing to profitability alongside volume growth.
  • At the same time, the forecasted earnings growth rate of about 11.25% per year is below the very strong 53.6% reported improvement, which suggests the consensus view already bakes in a moderation from recent performance.

Thin 1.1% margins in a high volume business

• McKesson reports a trailing net profit margin of 1.1% on roughly US$398.0b of revenue, compared with 0.8% a year earlier, highlighting how small changes in margin can move profit on a very large revenue base.
• Supporters of the bullish view argue that investments in digitization, automation, and higher value services can steadily support margins. The move from 0.8% to 1.1% is consistent with that, while still leaving margins low enough that changes in pricing or costs could have a meaningful impact on earnings.
  • Consensus commentary points to automation in distribution and logistics, and services like pharmacy management and patient access solutions, as ways to reduce operating expense intensity and deepen customer relationships on the same revenue base.
  • Bearish concerns around lower margin generics and biosimilars are also present in the narrative, and the current 1.1% margin shows that even with some improvement, the business remains sensitive to any mix shift toward products or contracts with tighter spreads.

P/E of 21.3x and DCF fair value gap

• The stock trades on a trailing P/E of 21.3x at a share price of US$754.76, slightly below the US Healthcare industry average of 22.4x and slightly above the peer average of 20.4x, while a DCF fair value of about US$1,444.63 implies the price is roughly 47.8% below that estimate.
• Bulls highlight that historical earnings growth of 49.5% per year over five years, together with a 53.6% increase in earnings over the last year and a forecast growth rate of about 11.25% per year, helps support the case that paying 21.3x trailing earnings could be reasonable even with high reported debt and revenue growth that is below broader US market forecasts.
  • Analyst expectations for revenue growth of around 7.6% per year and modest margin expansion from 1.1% to 1.2% suggest the current P/E and DCF fair value gap are tied to a view that steady, rather than rapid, growth continues from this earnings base.
  • The flagged high debt level sits alongside these valuation signals and gives cautious investors a concrete factor to weigh against the implied upside from both the DCF fair value of US$1,444.63 and the analyst price target of US$990.87 compared with the current US$754.76 share price.

On numbers like these, many investors want to see how a full bull case connects Q3 margins, growth forecasts, and long term earnings power, which is exactly what the 🐂 McKesson Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for McKesson on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages in the numbers or a clear setup taking shape, either way it helps to see the full risk and reward picture before deciding, including the 4 key rewards and 1 important warning sign.

Explore Alternatives

McKesson's thin 1.1% net margin on a very large revenue base and its highlighted high debt level leave limited room for error if conditions tighten.

If that tight margin and debt profile make you cautious, compare it with companies in the solid balance sheet and fundamentals stocks screener (44 results) to see businesses built on sturdier financial foundations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.